← Oncology Approval Tracker

FDA DECISION ·

Lymphir

denileukin diftitox-cxdl · Citius Pharmaceuticals

FDA approvalNew therapyCutaneous T-cell lymphoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with relapsed or refractory stage I to III cutaneous T-cell lymphoma after at least one systemic treatment.

LAMPGEN ANALYSIS

Why it matters

This IL-2 receptor-directed fusion protein adds an option in previously treated cutaneous T-cell lymphoma.

What research teams should watch

Set up skin disease scoring and watch for capillary leak with serial weight, vital signs and albumin review.

PRIMARY RECORDS

Sources